Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics teams up with Ergomed to take its anti-allergy tablets through the clinic

Allergy already has injectable vaccines for dust mites and tree and grass pollen, but it has brought in Ergomed to take the tablet formulations through clinical trials
woman with allergy
The tablets have been available in some European countries for a little while but only on a ‘named-patient basis’

Allergy vaccine maker Allergy Therapeutics plc (LON:AGY) has teamed up with fellow AIM company Ergomed Plc (LON:ERGO) to progress the clinical development of three of its OralVac immunotherapy products.

Under the terms of the co-development collaboration agreement, Ergomed will take the treatments for dust mite, tree pollen and grass pollen allergies through the clinic.

READ: Ergomed hopes to have PeproStat on the market by 2020 as it sails through Phase II trials

The development, which is scheduled to last for seven years, will kick off next year with a phase I study in the dust mite OralVac tablet.

Allergy Therapeutics already has injectable vaccines for those three allergies but wants to broaden its offering to cater for patients who don’t like needles and would prefer a pill.

The oral formulation has been available for more than two decades in Germany and other European countries but on a ‘named-patient basis’, which means doctors will only prescribe them in special cases.

Ergomed will receive a fee for conducting the clinical development activities although it will also be expected to stump to contribute some of the development costs.

In return, the company will receive future tiered royalties for each product once the first phase II study has been completed.

"We are pleased to announce this co-development programme with Ergomed, which is aimed at strengthening our product portfolio across Europe in a risk-sharing fashion,” said Allergy Therapeutics chief executive Manuel Llobet.

READ: Allergy Therapeutics - strong financial showing, solid cash position, progress in the clinic

“Ergomed has over 20 years of experience in clinical development and significant expertise in the allergy field, and are thus ideally placed to support us in the progression of our OralVac products.”

Ergomed executive vice chairman Miroslav Reljanovic added: “We are excited to join in the further development of these products which have established an important presence in the market.

“Ergomed has extensive experience in conducting clinical research in the field of allergy therapies, and so this is a natural therapy area for our next co-development project.”

Allergy shares rose 3% to 29p early on Tuesday, while Ergomed edged 0.5% higher to 185p.

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

July 02 2018
The research and diagnostic company develops cancer-detecting blood tests
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use